Copyright © 2023, StatPearls Publishing LLC.: Treasure Island (FL).
Rani, K., ATHEROSCLEROSIS AND ITS MEDICAL MANAGEMENT: A BRIEF COMPREHENSIVE REVIEW ON ITS ASSOCIATED CLINICAL IMPLICATIONS. International Journal of Biopharmaceutics, 2015. 6: p. 129-133.
Robinson, J.G., et al., Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. 2018. 7(20): p. e009778.
Ference, B.A., et al., Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2017. 38(32): p. 2459-2472.
Pantoja-Torres, B., et al., High triglycerides to HDL-cholesterol ratio is associated with insulin resistance in normal-weight healthy adults. Diabetes Metab Syndr, 2019. 13(1): p. 382-388.
Ridker, P.M., et al., Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. The Lancet.
Sniderman, A.D., et al., Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiology, 2019. 4(12): p. 1287-1295.
Simes, J., et al., D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease: LIPID Study. Circulation, 2018. 138(7): p. 712-723.
Florvall, G., S. Basu, and A. Larsson, Apolipoprotein A1 Is a Stronger Prognostic Marker Than Are HDL and LDL Cholesterol for Cardiovascular Disease and Mortality in Elderly Men. The Journals of Gerontology: Series A, 2006. 61(12): p. 1262-1266.
Albers, J.J., J.L. Adolphson, and W.R. Hazzard, Radioimmunoassay of human plasma Lp(a) lipoprotein. J Lipid Res, 1977. 18(3): p. 331-8.
Pechlaner, R., et al., Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III. J Am Coll Cardiol, 2017. 69(7): p. 789-800.
Shapiro, M.D. and S. Fazio, Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease. F1000Res, 2017. 6: p. 134.
Makover, M.E., M.D. Shapiro, and P.P. Toth, There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness. Am J Prev Cardiol, 2022. 12: p. 100371.
O'Keefe, J.H., Jr., et al., Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol, 2004. 43(11): p. 2142-6.
Wang, N., et al., Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis. 2022. 15(6): p. e008552.
Boekholdt, S.M., et al., Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins: A Meta-analysis. JAMA, 2012. 307(12): p. 1302-1309.
Law, M.R., N.J. Wald, and A.R. Rudnicka, Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Bmj, 2003. 326(7404): p. 1423.
Xuan, K., et al., The efficacy of statins in the treatment of Alzheimer’s disease: a meta-analysis of randomized controlled trial. Neurological Sciences, 2020. 41(6): p. 1391-1404.
Mensink, R.P. and O. World Health, Effects of saturated fatty acids on serum lipids and lipoproteins: a systematic review and regression analysis. 2016, Geneva: World Health Organization.